Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics posts $16.3 million Q3 net loss; cash funds operations only into Q1 2027

Mixed Impact 3 of 5 earnings Written later

Seres reported a third-quarter 2026 net loss of $16.3 million, compared with net income of $8.2 million a year earlier, when a $25 million VOWST sale installment was recognized as a gain. The company said its cash and cash equivalents of $17.5 million at September 30, 2026, plus a $12.5 million payment from Nestlé received in October, fund operations only through the first quarter of 2027, excluding any new partnership or capital proceeds.

Key points

  • Q3 2026 net loss of $16.3 million (-$1.63 per share) vs. net income of $8.2 million ($0.94 per share) in Q3 2025
  • Grant revenue rose to $593 thousand from $351 thousand; R&D expenses fell to $5.6 million from $12.6 million, and G&A to $5.4 million from $9.5 million
  • A $5.7 million non-cash impairment charge related to the early termination of the 200 Sidney Street lease
  • Cash runway expected through Q1 2027; company plans to submit an irEC study design to the FDA in Q1 2027 and says funding is required

The filing

CompanySeres Therapeutics, Inc. (MCRB)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:05 AM ET
Accession number0001193125-26-446185

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.